A complement-blocking drug cut urine protein by nearly half in IgA nephropathy
In an interim analysis of a phase 3 trial published Oct. 23, 2026, in the New England Journal of Medicine, ravulizumab lowered urine protein by 46.6% at week 34 in IgA nephropathy,…